EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetics and Bioequivalence Evaluation of Two Different Aildenafil Citrate Tablet Formulations in Healthy Chinese Male Subjects Under Fasting and Fed Conditions

Hegui Yan, Yu Peng, Zhixiang Pan, Yiyi Wang, Quan Li, Guan Liu

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.1571 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Hegui Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Research Center, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, China. Hauptthemen laut MEDLINE: Fasting, Food-Drug Interactions, Phosphodiesterase 5 Inhibitors, Piperazines. Die Arbeit nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aildenafil citrate is a novel and potent phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction (ED). This study evaluates the pharmacokinetics and bioequivalence of 2 formulations of aildenafil citrate tablets (30 and 60 mg) in healthy Chinese male subjects under both fasting and fed conditions. A single‐center, randomized, open‐label, 2‐period crossover design was employed, with 78 participants enrolled, including 30 in the fasting condition and 48 in the fed condition. Blood samples were collected at multiple time points for pharmacokinetic analysis, which included C max , AUC 0‐t , and AUC 0‐∞ as the primary parameters. The results demonstrated that the pharmacokinetic profiles of the test and reference formulations were comparable in both the fasting and fed states, with 90% confidence intervals for the geometric mean ratios of C max , AUC 0‐t , and AUC 0‐∞ falling within the 80%‐125% range, confirming bioequivalence. Although food intake slightly delayed the time to peak concentration and reduced the absorption rate, it did not significantly affect the overall bioavailability. Both formulations were well tolerated, with adverse events being mild and resolving spontaneously. This study provides evidence supporting the bioequivalence of the 2 aildenafil citrate formulations and their interchangeability for clinical use in treating ED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FastingFood-Drug InteractionsPhosphodiesterase 5 InhibitorsPiperazinesAdultHumansMaleYoung AdultAdministration, OralArea Under CurveBiological AvailabilityCross-Over StudiesHealthy VolunteersTabletsTherapeutic EquivalencyChina

Stichwörter der Autor:innen

aildenafil citratebioequivalenceerectile dysfunctionpharmacokineticssafety

Substanzen

Phosphodiesterase 5 InhibitorsPiperazinesTablets

Autor:innen und Institutionen

  • Phase I Clinical Research Center, Wuhan Pulmonary Hospital, Wuhan Institute of Tuberculosis Prevention and Control, Wuhan, China.

Zitieren

APA

Yan, H., Peng, Y., Pan, Z., Wang, Y., Li, Q., & Liu, G. (2026). Pharmacokinetics and Bioequivalence Evaluation of Two Different Aildenafil Citrate Tablet Formulations in Healthy Chinese Male Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1571

Vancouver

Yan H, Peng Y, Pan Z, Wang Y, Li Q, Liu G. Pharmacokinetics and Bioequivalence Evaluation of Two Different Aildenafil Citrate Tablet Formulations in Healthy Chinese Male Subjects Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.1571

BibTeX
@article{Yan2026,
  author = {Yan, Hegui and Peng, Yu and Pan, Zhixiang and Wang, Yiyi and Li, Quan and Liu, Guan},
  title = {Pharmacokinetics and Bioequivalence Evaluation of Two Different Aildenafil Citrate Tablet Formulations in Healthy Chinese Male Subjects Under Fasting and Fed Conditions},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.1571}
}
Kostenlos starten →